Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Essai therapeutique randomise Multicentrique en Double Insu, Comparant l'enoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanee Quotidienne, Dans Les Fausses Couches spontanees recurrentes inexpliquees.

Trial Profile

Essai therapeutique randomise Multicentrique en Double Insu, Comparant l'enoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanee Quotidienne, Dans Les Fausses Couches spontanees recurrentes inexpliquees.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Spontaneous abortion
  • Focus Therapeutic Use
  • Acronyms PREFIX

Most Recent Events

  • 21 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 28 Jun 2013 Planned End Date changed from 1 Jan 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
  • 28 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top